News archive 2006

19 December 2006
Analysis by AlgoNomics reveals that Anticalins have an immunogenicity level comparable to the wild-type human lipocalin

13 December 2006
ABLYNX Identified Novel NANOBODIES® Achieving First Milestone in PROCTER & GAMBLE Collaboration

6 December 2006
Gilde sells its stake in Inpharmatica to Galapagos N.V.

1 December 2006
GILDE portfolio company Innate Pharma successfully completed its IPO on EURONEXT

1 December 2006
BG Medicine and Royal Philips Electronics establish a large industry consortium with Merck, AstraZeneca and Humana

1 December 2006
Molecular Therapeutics BV (AMT) Acquires License to AAV Patents from Targeted Genetics Corporation

15 November 2006
Agendia announces a distribution agreement with Teva & Tuteur, Argentina

15 November 2006
IDEA AG receives approvable letter from Swissmedic for IDEA-033

6 November 2006
ABLYNX Enters into a Research and License Agreement with Wyeth

25 October 2006
PIERIS confirms in vivo activity of potent VEGF-specific Anticalin®

16 October 2006
ABLYNX Expands and Relocates to New Facilities

6 September 2006
Agendia's MammaPrint® breast cancer prognosis test validated by an independent international consortium

3 July 2006
AGENDIA's MammaPrint® breast cancer prognosis test validated by an independent international consortium

3 July 2006
AGENDIA acquires ISO accreditation for CupPrint® diagnostic service

3 July 2006
AGENDIA's MammaPrint® shows significant agreement with other multi-gene breast cancer prognosis tests

3 July 2006
BG MEDICINE - Philips and BG Medicine Form Alliance for Molecular Medicine Research and Development

3 July 2006
Gilde raises EUR 85 million (USD 107 million) for its Second Healthcare Fund

1 July 2006
ABLYNX Strengthens Management Team - Eva-Lotta Allan Joins as Chief Business Officer

1 July 2006
AGENDIA BV Closes Third Financing Round

1 July 2006
PIERIS Appoints New Chief Executive Officer

1 July 2006
GILDE sells its equity stake in CropDesign to BASF

1 July 2006
ABLYNX Appoints Wim Ottevaere as CFO

1 July 2006
PIERIS Enters into Collaborative Research Agreement with GE Healthcare

1 July 2006
ABLYNX and PROCTER & GAMBLE Extend NANOBODY™ Drug Discovery and Development Agreement to Metabolic Targets

1 July 2006
INNATE PHARMA and Novo Nordisk announce strategic partnership to research and develop drugs targeting natural killer cells

1 July 2006
CHROMA THERAPEUTICS Completes $53 Million Series C Financing

3 April 2006
INPHARMATICA'S ADMENSA INTERACTIVE™ Licensed by Lilly

3 April 2006
INNATE PHARMA Strengthens Its Platform in the Pharmacology of Toll-Like Receptors (TLR) with Assets Licensed from US-Based Global Pharmaceutical Company Schering-Plough Corporation

3 April 2006
PIERIS Appoints Dr. Andreas Holbaum as Member of its Management Team

1 January 2006
CHROMA THERAPEUTICS and DISCOVERY PARTNERS INTERNATIONAL, Inc. Entered Into a Collaboration for Lead Identification on Multiple Targets

1 January 2006
AGENDIA announces a distribution agreement with Opaldia to introduce its validated MammaPrint®

1 January 2006
BG Medicine signs Biomarker Discovery Agreement with Mitsubishi

1 January 2006
ABLYNX Appoints Edwin Moses as CEO

1 January 2006
INPHARMATICA Announces Collaboration Agreement with Ingenuity Systems, Inc.

1 January 2006
ABLYNX Reveals Power of NANOCLONE™

1 January 2006
INPHARMATICA Extends ADMENSA INTERACTIVE™

1 January 2006
BG Medicine and TB Alliance Initiate Biomarker Discovery Program

1 January 2006
AGENDIA announces a distribution agreement with Gene Care to introduce its validated MammaPrint®

1 January 2006
ABLYNX Announces Research Collaboration with Kirin Brewery

1 January 2006
ABLYNX Announces Pharma Alliance to Develop Therapeutic Nanobodies

1 January 2006
ABLYNX Announces Collaboration with Centocor Research and Development, Inc.

Bottles with golden caps